Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

QA102 Fase II-studie i forsøkspersoner med tørr AMD (AMEND)

8. september 2026 oppdatert av: Smilebiotek Zhuhai Limited

En fase 2, dobbeltmasket, randomisert, placebokontrollert, dose-respons-studie som vurderer sikkerheten og effekten av QA102 hos personer med tørr aldersrelatert makuladegenerasjon (AMD)

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

Studieoversikt

Detaljert beskrivelse

Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.

Studietype

Intervensjonell

Registrering (Faktiske)

150

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forente stater, 85021
        • Associated Retina Consultants
    • California
      • Mountain View, California, Forente stater, 94040
        • Northern California Retina Vitreous Associates Medical Group
      • Pasadena, California, Forente stater, 91107
        • California Eye Specialists Medical Group
      • Redlands, California, Forente stater, 91107
        • California Eye Specialists Medical Group
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80909
        • Retina Consultants of Southern Colorado, P.C.
    • Florida
      • Deerfield Beach, Florida, Forente stater, 33064
        • Advanced Research
      • Fort Myers, Florida, Forente stater, 33912
        • National Ophthalmic Research Institute
      • Miami, Florida, Forente stater, 33143
        • MedEye Associates
      • Pensacola, Florida, Forente stater, 32503
        • Retina Specialty Institute
      • Pinellas Park, Florida, Forente stater, 33782
        • Eye Associates of Pinellas
      • Sarasota, Florida, Forente stater, 34239
        • Sarasota Retina Institute
      • Winter Haven, Florida, Forente stater, 33880
        • Vitreous and Retina Consultants
    • Georgia
      • Marietta, Georgia, Forente stater, 30060
        • Marietta Eye Clinic
    • Illinois
      • Oak Forest, Illinois, Forente stater, 60452
        • University Retina and Macula Associates
    • Louisiana
      • West Monroe, Louisiana, Forente stater, 71291
        • Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Baltimore, Maryland, Forente stater, 21209
        • The Retina Care Center
      • Hagerstown, Maryland, Forente stater, 21740
        • Cumberland Valley Retina Consultants
      • Hagerstown, Maryland, Forente stater, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Worcester, Massachusetts, Forente stater, 01605
        • Vitreo-Retinal Associates, P.C.
    • Missouri
      • St Louis, Missouri, Forente stater, 63144
        • Retina Research Institute
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45202
        • Velocity Clinical Research
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Verum Research, LLC
    • Pennsylvania
      • Erie, Pennsylvania, Forente stater, 16507
        • Erie Retina Research
    • Texas
      • Abilene, Texas, Forente stater, 79606
        • Retina Research Institute of Texas
      • Austin, Texas, Forente stater, 78705
        • Austin Research Center for Retina
      • Dallas, Texas, Forente stater, 75243
        • AXIS Clinicals LLC / Retina of North Texas
      • Plano, Texas, Forente stater, 75075
        • Texas Retina Associates - Plano
      • San Antonio, Texas, Forente stater, 78215
        • San Antonio Eye Center
    • Utah
      • Salt Lake City, Utah, Forente stater, 84107
        • Rocky Mountain Retina Consultants

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
  • Subject must be age ≥50 years at the time of informed consent.
  • Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
  • Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
  • Subject must be willing and able to comply with study procedures and examinations.

Specific to the Study Eye:

  • Subject must have one of the following:

    • extensive intermediate-size drusen, or at least 1 large drusen, or
    • GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
  • Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).

Specific to Fellow Eye:

- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.

Specific to Both Eyes:

- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.

Key Exclusion Criteria:

  • Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
  • Subject has ever received gene therapy (for any condition).
  • Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
  • Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
  • Subject had major surgery within 30 days prior to Screening.

Specific to Study Eye:

  • Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
  • Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
  • Subject has endophthalmitis.
  • Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
  • Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
  • Subject has aphakia or absence of the posterior capsule.
  • Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)

Specific to Fellow Eye:

Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.

Specific to Either Eye:

  • Subject had intraocular surgery with lens replacement within 3 months of Screening.
  • Subject has any ophthalmic condition that could require surgery during the study period.
  • Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: QA102 200mg group

Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months

Capsules

Eksperimentell: QA102 400mg group

Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months

Capsules

Placebo komparator: Placebo group

Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months

Capsules

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Soft Drusen Volume (mm3)
Tidsramme: Month 12

Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set

Month 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean Rate of GA Growth
Tidsramme: Month 12

Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline

Month 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. september 2022

Primær fullføring (Faktiske)

12. november 2024

Studiet fullført (Faktiske)

12. november 2024

Datoer for studieregistrering

Først innsendt

8. september 2022

Først innsendt som oppfylte QC-kriteriene

8. september 2022

Først lagt ut (Faktiske)

13. september 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • QA102-CS201

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere